{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-008459","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.595887+00:00","generated_at":"2026-06-18T00:30:06.996849+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Trevi Therapeutics reports Q4 2022 net loss $5.5M; cash $120.5M into 2026","bullets":["Net loss Q4 2022: $5.5M ($0.05 per share) vs $8.5M loss same period 2021. Full-year loss $29.2M vs $33.9M.","Cash, equivalents, and marketable securities $120.5M; expects cash runway into 2026.","Plans Phase 2b dose-ranging trial of Haduvio for IPF chronic cough in H2 2023; Phase 1b respiratory study also H2 2023.","Phase 2a trial in refractory chronic cough expected to start Q3 2023.","Open-label extension data from Phase 2b/3 PRISM trial in prurigo nodularis expected Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-008459","json":"https://secwatch.observer/filing/0000950170-23-008459.json","markdown":"https://secwatch.observer/filing/0000950170-23-008459.md","text":"https://secwatch.observer/filing/0000950170-23-008459.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000095017023008459/0000950170-23-008459-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000095017023008459/trvi-20230316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T00:30:06.996849+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d3f16cb24470063dadd1e58d8f827b58b1a1cfc5","claim":"Trevi Therapeutics, Inc. reported quarter and year ended December 31, 2022 results: net income net loss of $5.5 million.","evidence_excerpt":"announced its financial results for the quarter and year ended December 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017023008459/0000950170-23-008459-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter and year ended December 31, 2022"},{"label":"Net income","value":"net loss of $5.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}